Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies

被引：72

作者：

Wong, Rachel ^{[1
]}

Cunningham, David ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 35期

关键词：

D O I：

10.1200/JCO.2008.19.5024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5668 / 5670

页数：3

共 27 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2]

[Anonymous], 2008, Journal of Clinical Oncology

[3]

Baron AT, 2003, CANCER EPIDEM BIOMAR, V12, P103

[4] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[5] Bleomycin in testicular cancer: Will pharmacogenomics improve treatment regimens? [J].

Bokemeyer, Carsten .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1783-1785

[6] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[7] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[8] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].

Di Nicolantonio, Federica ;

Martini, Miriam ;

Molinari, Francesca ;

Sartore-Bianchi, Andrea ;

Arena, Sabrina ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712

[9] PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients [J].

Frattini, M. ;

Saletti, P. ;

Romagnani, E. ;

Martin, V. ;

Molinari, F. ;

Ghisletta, M. ;

Camponovo, A. ;

Etienne, L. L. ;

Cavalli, F. ;

Mazzucchelli, L. .

BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1139-1145

[10] Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma [J].

Hijiya, Naoki ;

Miyawaki, Michiyo ;

Kawahara, Katsunobu ;

Akamine, Shinji ;

Tsuji, Koh-Ichi ;

Kadota, Jun-Ichi ;

Akizuki, Shin'ichiro ;

Uchida, Tomohisa ;

Matsuura, Keiko ;

Tsukamoto, Yoshiyuki ;

Moriyama, Masatsugu .

HUMAN PATHOLOGY, 2008, 39 (03) :316-323

← 1 2 3 →